Disclaimer Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements. This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933. This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus. This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents. This press release does not constitute an "offer of securities to the public" within the meaning of Directive 2003/71/ EC of the European Union (the "Prospectus Directive") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities. ----------------------------------------------------------------------------------------------------------------------- Ende der Ad-hoc-Mitteilung ----------------------------------------------------------------------------------------------------------------------- 


Sprache:      Deutsch 
Unternehmen:  Cosmo Pharmaceuticals N.V. 
              Riverside 2, Sir John Rogerson's 
              Dublin 2 Dublin 
              Irland 
Telefon:      + 353 1 817 0370 
E-Mail:       info@cosmopharma.com 
Internet:     https://www.cosmopharma.com/ 
ISIN:         NL0011832936 
Börsen:       SIX Swiss Exchange 
EQS News ID:  1222892 
 
Ende der Mitteilung EQS Group News-Service 
=------------

1222892 2021-07-30 GMT/BST


 
Bildlink: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1222892&application_name=news

(END) Dow Jones Newswires

July 30, 2021 01:00 ET (05:00 GMT)